Pfizer's CDK4/6 inhibitor approved for advanced breast cancer

E-resources

Peer reviewed

Pfizer's CDK4/6 inhibitor approved for advanced breast cancer

Morrison, Chris

Nature biotechnology, 04/2015, Volume: 33, Issue: 4

Journal Article

The first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor was okayed by the US Food and Drug Administration (FDA) February 3, as New York-based Pfizer received accelerated approval for Ibrance (palbociclib) based on phase 2 data. The drugs go-ahead is for use as a frontline treatment in combination with letrozole (Femara), a standard anti-estrogen therapy, in postmenopausal women with estrogen receptor (ESR)-positive human epidermal growth factor receptor-2 (HER2)-negative (ESR+/HER2) advanced breast cancer.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme